as 10-17-2024 4:00pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Founded: | 2021 | Country: | Switzerland |
Employees: | N/A | City: | ZUG |
Market Cap: | 2.9B | IPO Year: | N/A |
Target Price: | $78.00 | AVG Volume (30 days): | 440.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.92 | EPS Growth: | N/A |
52 Week Low/High: | $35.11 - $64.98 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
BVF PARTNERS L P/IL | MLTX | Director10% Owner | Oct 4 '24 | Sell | $50.00 | 2,000,000 | $100,003,200.00 | 10,235,089 |
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
Argus Research
9 days ago
GuruFocus.com
9 days ago
MT Newswires
9 days ago
Insider Monkey
23 days ago
Insider Monkey
25 days ago
GlobeNewswire
a month ago
Insider Monkey
2 months ago
MT Newswires
2 months ago
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.